SOURCE: Easton Pharmaceuticals Inc

Easton Pharmaceuticals Inc

February 17, 2015 09:00 ET

Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015

HUMBOLDT, CA--(Marketwired - Feb 17, 2015) - Easton Pharmaceuticals Inc (OTC PINK: EAPH) unveils Medicated Markets revenue projections for fiscal year 2015.

In January of 2015, prices have increased for medicinal marijuana to $2185.00 per pound In California (dispensaries in the greater LA region as clarified in past communications) as an average. This is a marked increase from December 2014 prices of $1925.00 per pound. Revenue distribution is expected be stable throughout the year as a growth cycle is used for plants in various stages of development. Yield in prior harvests have consistently yielded 1.5 lbs per plant on average.

Clone to Sale revenue guidance are as follows:

Total plants grown being 10,000 x 1.5lbs yield = 15,000 lbs x $2185.00 approximate sales price

Revenue based on these targets stand at $32,775,000

In other related news, Easton Pharmaceuticals have initiated discussions with a Canadian MMAR Licensed grower to obtain legal active cannabinoids for its OTC topical formulations.

Questions relating to Medicated Markets Operations should be sent to info@medicatedmarkets.com where quick responses to any queries can be expected.

Mr. M Farrugia asked if any portion of future marijuana product has been pre-sold to lock in prices and when an expected 8K filing related to this transaction is to be made public. Our current dispensaries are allowed to purchase up to 60 days prior to delivery on any specific strains to maintain availability at their locations. An 8K filing is to be soon be disclosed by Easton. 

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system needed for growing pesticide free medicine, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com/
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

Contact Information